Welcome to our dedicated page for ALNYLAM PHARMACEUTICALS SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
Alnylam Pharmaceuticals reported higher revenue for the quarter ended June 30, 2026, with total revenues of 1,290,948, up from 773,689 a year earlier. Net product revenues rose to 1,172,109, led by AMVUTTRA at 1,011,762, while Rare disease products contributed 141,886. The company generated net income of 164,494 for the quarter and 370,485 for the first half, reversing prior-year losses.
Liquidity remains robust, with cash and cash equivalents of 1,708,318 and marketable debt securities of 1,599,829 as of June 30, 2026. Operating cash flow for the first half improved to 397,228. Stockholders’ equity increased to 1,354,118, while convertible debt totaled 1,010,981.
Alnylam continues to advance its RNAi-based pipeline and collaborations. The Roche zilebesiran agreement carried a total transaction price of 1,738,167, with 77,529 in related collaboration revenue recognized year‑to‑date. The company also recorded 51,356 in collaboration revenue from Regeneron and entered an AI‑driven discovery collaboration with Inceptive Nucleics, including a 15,000 preferred equity investment.
Alnylam Pharmaceuticals reported strong second-quarter 2026 results, with total revenues of $1,290,948 thousand, up 67% from Q2 2025. Net product revenues were $1,172,109 thousand, a 74% increase, led by AMVUTTRA and ONPATTRO TTR therapies generating $1,030,223 thousand, an 89% rise.
GAAP income from operations was $231,441 thousand versus a prior-year loss, and GAAP net income reached $164,494 thousand, while non-GAAP net income was $251,801 thousand and diluted non-GAAP EPS was $1.84. Cash, cash equivalents and marketable securities totaled $3.3 billion as of June 30, 2026, supported by net cash inflows from operating activities.
The company updated 2026 guidance to $4,200–$4,500 million in TTR net product revenues and $4,700–$5,100 million in total net product revenues. Expected 2026 net revenues from collaborations and royalties were raised to $575–$625 million, and non-GAAP R&D and SG&A expense guidance of $2,700–$2,800 million was reiterated.
ALNYLAM PHARMACEUTICALS, INC. director David E I Pyott exercised a stock option for 3,830 shares of common stock at a conversion price of $70.20 per share and sold the same 3,830 shares in open-market transactions on June 1, 2026. The reported sales occurred at weighted average prices around $297.71–$302.65 per share under a pre-arranged Rule 10b5-1(c) trading plan, and the options were due to expire on June 3, 2026. Following these transactions, he holds 1,582 shares of common stock directly and 27,900 shares indirectly through the David E I Pyott Trust, of which he is trustee.
ALNYLAM PHARMACEUTICALS, INC. director Benjamin Cravatt reported a compensation-related stock option grant. He received options to buy 4,393 shares of common stock at an exercise price of $295.63 per share. The options vest in three equal annual installments starting on the first anniversary of the grant date and expire in 2036. Following this grant, he holds 4,393 derivative securities directly.
ALNYLAM PHARMACEUTICALS, INC. director Benjamin Cravatt has filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. This filing lists him as a director of the company but does not report any stock transactions or specific holdings in this excerpt.
Alnylam Pharmaceuticals, Inc. expanded its Board of Directors from ten to eleven members, appointing Benjamin F. Cravatt, Ph.D. as a Class III director effective June 1, 2026, with a term running until the 2028 annual stockholder meeting. He will also join the Board’s Science and Technology Committee.
As a non-employee director, Dr. Cravatt will receive a $75,000 annual cash retainer and an initial stock option grant with a $600,000 grant date fair value, vesting in three equal annual installments, with an exercise price set at the common stock closing price on the grant date.
The filing also reports results of the 2026 annual meeting. As of the March 25, 2026 record date, 133,427,910 common shares were outstanding. Stockholders re-elected three Class I directors, approved on an advisory basis the compensation of named executive officers, and ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for the year ending December 31, 2026.
ALNYLAM PHARMACEUTICALS, INC. director Charles Elliott Sigal reported new equity awards and updated holdings. He received 671 restricted stock units (RSUs), each representing a contingent right to one share of common stock, granted at no cash cost. These RSUs vest in full on the first anniversary of the grant date or upon an earlier qualifying retirement or resignation that occurs no more than 90 days before that anniversary. He was also granted a stock option for 1,441 shares of common stock at an exercise price of $298.48 per share, with the same vesting schedule and an expiration date in 2036. After these awards, he holds 1,446 common shares directly and 2,000 shares indirectly through Sigal Family Investments, LLC.
ALNYLAM PHARMACEUTICALS, INC. director Amy W. Schulman reported equity compensation awards rather than open-market trades. On May 20, 2026, she received 838 restricted stock units (RSUs), each representing one share of common stock, increasing her direct common stock holdings to 24,049 shares after the grant.
She was also granted stock options on 1,802 shares of common stock with a $298.48 exercise price, expiring on May 20, 2036. Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or a qualifying retirement or resignation that occurs no more than 90 days before that anniversary.
Alnylam Pharmaceuticals director Colleen F. Reitan received new equity awards as part of her compensation. She was granted 671 restricted stock units, each representing one share of common stock, increasing her direct holdings to 1,446 common shares after the award.
She also received a stock option covering 1,441 common shares at an exercise price of $298.48 per share. Both the RSUs and the option vest in full on the earlier of the first anniversary of the grant date or her earlier retirement or resignation, if that occurs no more than 90 days before the first anniversary.